WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has been named Best Contract Research Organization (CRO) in Asia at the World Vaccine Congress’ inaugural 2010 Vaccine Industry Excellence (ViE) Asia Awards held in Singapore on June 9. The award recognizes PPD’s quality of services provided in Asia and its long-standing client partnerships in the vaccine industry.

“Our large presence in China and strong expertise in vaccine clinical research well position us to advance our clients’ vaccine research and development programs and address unique requirements for managing vaccine studies in Asia,” said Simon Britton, PPD’s vice president of clinical development for Asia Pacific. “We are pleased the World Vaccine Congress has recognized our client relationships and investments in the growing vaccine industry.”

PPD has delivered full-service, global vaccine development services to biopharmaceutical companies and government and nongovernment organizations for more than 20 years. In April, the company opened a vaccine clinical research center at the Taizhou China Medical City in Taizhou, China, further strengthening its clinical research and development services in one of the country’s major regions for conducting vaccine studies. Through the center, PPD provides clinical monitoring services to companies seeking to develop vaccines in China.

PPD also launched its Vaccines & Biologics Center of Excellence earlier this year, which is a first-in-kind comprehensive network of integrated, world-class laboratory services focused on vaccine and biologic drug development. The center advances PPD's position as the industry leader in providing testing services for vaccines and other biologics with state-of-the-art facilities, processes and instrumentation to help clients realize the highest scientific standards and cost efficiencies for their programs.

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about PPD’s selection as best contract research organization in Asia, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: success in sales growth; competition in the outsourcing industry; rapid technological advances that make our services less competitive; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; dependence on collaborative relationships; the ability to attract and retain key personnel; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

PPD, Inc.
Media:
Louise Caudle, 919-456-4467
louise.caudle@ppdi.com
Analysts/Investors:
Luke Heagle, 910-558-7585
luke.heagle@ppdi.com